Literature DB >> 16468815

Synthesis of xyloketal A, B, C, D, and G analogues.

Jeremy D Pettigrew1, Peter D Wilson.   

Abstract

A series of demethyl analogues of the natural products xyloketal A, B, C, D, and G have been prepared in a notably direct manner from 3-hydroxymethyl-2-methyl-4,5-dihydrofuran and a series of corresponding phenols. These syntheses featured a boron trifluoride diethyl etherate-promoted electrophilic aromatic substitution reaction as a key step. In the case of the synthesis of analogues of xyloketal A, the process was found to be highly efficient (up to 93% yield). The optimized isolated yield of these reaction products is remarkable in view of the fact that this transformation involves, minimally, six individual reactions. Moreover, these synthetic studies provide significant insight into the possible biogenic origin of the xyloketal natural products.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16468815     DOI: 10.1021/jo052371+

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  11 in total

1.  Xyloketal B exerts antihypertensive effect in renovascular hypertensive rats via the NO-sGC-cGMP pathway and calcium signaling.

Authors:  Li-Yan Zhao; Jie Li; Xiong-Qing Huang; Guo-Hao Wang; Xiao-Fei Lv; Wei-Feng Meng; Wen-Liang Chen; Ji-Yan Pang; Yong-Cheng Lin; Hong-Shuo Sun; Guan-Lei Wang; Yao-Min Du
Journal:  Acta Pharmacol Sin       Date:  2018-03-29       Impact factor: 6.150

2.  Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study.

Authors:  Junhui Su; Cui Chang; Qi Xiang; Zhi-Wei Zhou; Rong Luo; Lun Yang; Zhi-Xu He; Hongtu Yang; Jianan Li; Yu Bei; Jinmei Xu; Minjing Zhang; Qihao Zhang; Zhijian Su; Yadong Huang; Jiyan Pang; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2014-12-12       Impact factor: 4.162

3.  Xyloketal B attenuates atherosclerotic plaque formation and endothelial dysfunction in apolipoprotein e deficient mice.

Authors:  Li-Yan Zhao; Jie Li; Feng Yuan; Mei Li; Quan Zhang; Yun-Ying Huang; Ji-Yan Pang; Bin Zhang; Fang-Yun Sun; Hong-Shuo Sun; Qian Li; Lu Cao; Yu Xie; Yong-Cheng Lin; Jie Liu; Hong-Mei Tan; Guan-Lei Wang
Journal:  Mar Drugs       Date:  2015-04-14       Impact factor: 5.118

4.  Synthesis and neuroprotective action of xyloketal derivatives in Parkinson's disease models.

Authors:  Shichang Li; Cunzhou Shen; Wenyuan Guo; Xuefei Zhang; Shixin Liu; Fengyin Liang; Zhongliang Xu; Zhong Pei; Huacan Song; Liqin Qiu; Yongcheng Lin; Jiyan Pang
Journal:  Mar Drugs       Date:  2013-12-18       Impact factor: 5.118

5.  Design and synthesis of novel xyloketal derivatives and their protective activities against H2O2-induced HUVEC injury.

Authors:  Shixin Liu; Rong Luo; Qi Xiang; Xianfang Xu; Liqin Qiu; Jiyan Pang
Journal:  Mar Drugs       Date:  2015-02-12       Impact factor: 5.118

6.  Marine compound xyloketal B reduces neonatal hypoxic-ischemic brain injury.

Authors:  Ai-Jiao Xiao; Wenliang Chen; Baofeng Xu; Rui Liu; Ekaterina Turlova; Andrew Barszczyk; Christopher Lf Sun; Ling Liu; Marielle Deurloo; Guan-Lei Wang; Zhong-Ping Feng; Hong-Shuo Sun
Journal:  Mar Drugs       Date:  2014-12-24       Impact factor: 5.118

7.  Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models.

Authors:  Youying Zhang; Tian Meng; Ling Zuo; Yu Bei; Qihao Zhang; Zhijian Su; Yadong Huang; Jiyan Pang; Qi Xiang; Hongtu Yang
Journal:  Mar Drugs       Date:  2017-06-03       Impact factor: 5.118

8.  Xyloketal B suppresses glioblastoma cell proliferation and migration in vitro through inhibiting TRPM7-regulated PI3K/Akt and MEK/ERK signaling pathways.

Authors:  Wen-Liang Chen; Ekaterina Turlova; Christopher L F Sun; Ji-Sun Kim; Sammen Huang; Xiao Zhong; Yong-Yuan Guan; Guan-Lei Wang; James T Rutka; Zhong-Ping Feng; Hong-Shuo Sun
Journal:  Mar Drugs       Date:  2015-04-22       Impact factor: 5.118

9.  Identification of marine neuroactive molecules in behaviour-based screens in the larval zebrafish.

Authors:  Si-Mei Long; Feng-Yin Liang; Qi Wu; Xi-Lin Lu; Xiao-Li Yao; Shi-Chang Li; Jing Li; Huanxing Su; Ji-Yan Pang; Zhong Pei
Journal:  Mar Drugs       Date:  2014-05-30       Impact factor: 5.118

10.  Xyloketal derivative C53N protects against mild traumatic brain injury in mice.

Authors:  Fengyin Liang; Fengjuan Su; Xiaoxiao Wang; Simei Long; Yinglin Zheng; Xiaofei He; Jiyan Pang; Zhong Pei
Journal:  Drug Des Devel Ther       Date:  2018-12-27       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.